UNI-EN 19:Notification - Approval for transformation
Firma: SOPHARMA ADSpis treści:
1. REPORT
2. INFORMATION ABOUT THE ENTITY
3. SIGNATURE OF PERSONS REPRESENTING THE COMPANY
Spis załączników:
POLISH FINANCIAL SUPERVISION AUTHORITY | |||||||||||
| UNI - EN REPORT No | 19 | / | 2017 | |||||||
Date of issue: | 2017-04-26 | ||||||||||
Short name of the issuer | |||||||||||
SOPHARMA AD | |||||||||||
Subject | |||||||||||
Notification - Approval for transformation | |||||||||||
Official market - legal basis | |||||||||||
art. 17. 1 MAR. | |||||||||||
Unofficial market - legal basis | |||||||||||
Contents of the report: | |||||||||||
Sopharma AD (the “Company”) notifies that on 25 April 2017 the Financial Supervision Commission approved the Contract for transformation through merger and the additional annex to it, signed on 31 January 2017 between Sopharma AD, hereinafter referred to as "Acquirer" and Medica AD, hereinafter referred to as "Acquiree" in accordance with the requirements of art. 262d and following of the Commercial Act (CA). As a result the assets of Medica AD shall be transferred to Sopharma AD and the latter shall become its legal successor. Medica AD will be terminated without liquidation. The Financial Supervision Commission also approved the reports of the management of the two companies, prepared in accordance with the regulations of art.262i of the CA and the reports of the appointed examiners of the participants in the transformation under art. 262M of the CA from 13 October 2014. As a result of the merger, all shareholders of the Acquiree Medica AD, with the exception of the Acquirer Sopharma AD, which is also a shareholder of the Acquiree, will receive shares of Sopharma AD and become shareholders of it. Against one share of Medica AD each shareholder pursuant to art. 261b, art. 1 of the CA shall receive 0.8813 shares of the capital of Sopharma AD. The merger is subject to approval by the shareholders of the two companies on the respective General Meetings. | |||||||||||
Annexes | |||||||||||
File | Description | ||||||||||
Notification - Approval for transformation ENG.doc Notification - Approval for transformation ENG.doc | Notification - Approval for transformation |
SOPHARMA AD | |||||||||||||
(fullname of the issuer) | |||||||||||||
SOPHARMA AD | Farmaceutyczny (far) | ||||||||||||
(short name of the issuer) | (sector according to clasification of the WSE in Warsow) | ||||||||||||
1220 | Sofia | ||||||||||||
(post code) | (city) | ||||||||||||
IlienskoShosse | 16 | ||||||||||||
(street) | (number) | ||||||||||||
+359 2 813 42 00 | +359 2 936 02 86 | ||||||||||||
(phone number) | (fax) | ||||||||||||
(e-mail) | (web site) | ||||||||||||
nd | |||||||||||||
(NIP) | (REGON) |
SIGNATURE OF PERSONS REPRESENTING THE COMPANY | |||||
Date | Name | Position / Function | Signature | ||
2017-04-26 | Ognian Donev | Executive director |
Cena akcji Sopharma
Cena akcji Sopharma w momencie publikacji komunikatu to 7.31 PLN. Sprawdź ile kosztuje akcja Sopharma aktualnie.
W tej sekcji znajdziesz wszystkie komunikaty ESPI EBI Sopharma.